Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
BUSINESS
Drug Makers Terminate Lysozyme, Pronase Sale after MHLW Panel Finds Them Ineffective
Drug makers marketing enzyme preparations that contain lysozyme or pronase said on March 17 that they have decided to discontinue the sale of the products and started their voluntary recalls after a health ministry panel dismissed their efficacy earlier in…
To read the full story
Related Article
- Panel Finalizes “No Efficacy” Decision for Lysozyme, Pronase; MHLW Issues Notifications for Ethical, OTC Products
March 28, 2016
- Approvals for 3 Dasen-Like Drugs to Be Withdrawn
July 11, 2011
- Takeda to Voluntarily Recall Dasen
February 28, 2011
- Quick Answer Required on Efficacy of Dasen
February 14, 2011
- Dasen to Be Re-designated for Reevaluation
January 31, 2011
BUSINESS
- Japan Pharma Market Projected to Cross 12 Trillion Yen in FY2029: IQVIA
November 29, 2024
- Leqembi Now Available in South Korea: Eisai
November 29, 2024
- Pfizer Files Migraine Drug Rimegepant in Japan
November 28, 2024
- Dermatologist Hails Bimzelx as New Option for HS: UCB Seminar
November 27, 2024
- Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…